<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00798694</url>
  </required_header>
  <id_info>
    <org_study_id>08-875</org_study_id>
    <nct_id>NCT00798694</nct_id>
  </id_info>
  <brief_title>How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?</brief_title>
  <official_title>Ocular Surface Changes With Topical Prostaglandin Analog Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wills Eye</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wills Eye</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine whether one glaucoma eye drop is less
      likely to cause changes to the surface of the eye (conjunctiva) than another. The
      investigators plan to determine this theory by comparing the results when a patient is using
      two different prostaglandins, Xalatan and Travatan Z. (Both of these drops are presently on
      the market and are approved by the FDA for the treatment of eye pressure). Because this study
      will be masked, the clinician who reviews the study results will not know what study drop
      each patient has been using.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two groups will be entered into this study: group 1 will be naive to treatment and group 2
      will be using Xalatan for at least one month. Both groups will be using one drop at bedtime
      of Xalatan in the right eye and one drop at bedtime of Travatan Z in the left eye.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tear break up time (TBUT)</measure>
    <time_frame>2 months</time_frame>
    <description>Measurement made in seconds using a timer. Average of 3 measurements taken.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Conjunctival hyperemia</measure>
    <time_frame>2 months</time_frame>
    <description>Redness grading of the conjunctiva on a scale from 0 to 3 (none, mild, moderate and severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ocular surface disease index questionnaire</measure>
    <time_frame>2 months</time_frame>
    <description>Patient answers 12 questions regarding eye comfort under different conditions/environments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>impression cytology</measure>
    <time_frame>2 months</time_frame>
    <description>Looking for inflammatory cells in 4 quadrants on the conjunctiva</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>staining</measure>
    <time_frame>2 months</time_frame>
    <description>corneal staining with fluorescein and conjunctival staining with lissamine green</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>New to Meds</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Naive to glaucoma therapy medical or surgical. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Currently on Xalatan</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients currently on Xalatan at least one month. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xalatan</intervention_name>
    <description>one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime</description>
    <arm_group_label>New to Meds</arm_group_label>
    <arm_group_label>Currently on Xalatan</arm_group_label>
    <other_name>prostaglandin analog</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travatan Z</intervention_name>
    <description>one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime</description>
    <arm_group_label>New to Meds</arm_group_label>
    <arm_group_label>Currently on Xalatan</arm_group_label>
    <other_name>prostaglandin analog</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 21 or older

          -  Able to understand protocol and agree to 3 visits

          -  Any type of glaucoma

          -  SLT, ALT, PI accepted

          -  Naïve: No prior glaucoma treatment (medical or surgical)

          -  If pt non-compliant, must be off meds 3 months

          -  Xalatan: At least one month use

        Exclusion Criteria:

          -  Both Groups: Any history of ocular surface disease

          -  Dry eye syndrome or prior Restasis use

          -  Prior ocular surgery other than cataract extractions

          -  Uveitis or other inflammatory disease of the eye or adnexa

          -  Systemic medications that might influence ocular inflammation

          -  Any active inflammation or infection

          -  Pregnancy or intention to become pregnant

          -  Naïve: Prior use of topical glaucoma med unless off for 3 months.

          -  Use of preserved artificial tear preparations in last 30 days and more than one year
             history of chronic use

          -  Xalatan: Prior use of Travatan or Travatan Z
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>L Jay Katz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wills Eye Glaucoma Service</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wills Eye Glaucoma Service</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Gupta SR, Ichhpujani P, Wizov SS, Wittpenn JR, Moster MR, Pro MJ, Rapuano CJ, Cruz-Colon C, Myers JS, Katz LJ. Effects of Latanoprost Versus Travoprost with Sofzia on Ocular Surface. ARVO E-abstract 168/A391 2010</citation>
  </results_reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2008</study_first_submitted>
  <study_first_submitted_qc>November 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2008</study_first_posted>
  <last_update_submitted>December 20, 2012</last_update_submitted>
  <last_update_submitted_qc>December 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wills Eye</investigator_affiliation>
    <investigator_full_name>L. Jay Katz MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>impression cytology</keyword>
  <keyword>ocular surface changes</keyword>
  <keyword>prostaglandins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
    <mesh_term>Travoprost</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 7, 2016</submitted>
    <returned>February 5, 2016</returned>
    <submitted>November 26, 2016</submitted>
    <returned>January 20, 2017</returned>
    <submitted>November 27, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>December 14, 2017</submitted>
    <returned>January 11, 2018</returned>
    <submitted>March 13, 2018</submitted>
    <returned>April 13, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

